Evidence map›Paper›PMID 26264448›Full record

ArticleAddiction (Abingdon, England)2015

Vaping cannabis (marijuana): parallel concerns to e-cigs?

Alan J Budney, James D Sargent, Dustin C Lee

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. ΔCannabis and cannabinoid research · 2024
    Article
  16. Role of Cannabinoids in Oral Cancer.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Examining indirect effects of advertising exposure on young adults' cannabis and nicotine vaping.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023
    Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alan J BudneyGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
James D SargentGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
Dustin C LeeGeisel School of Medicine at Dartmouth, Hanover, NH, USA.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Treatment Development & Evaluation CoreP30DA029926 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2011 to 2026
$21.5M
Behavioral Treatment of Adolescent Marijuana UseR01DA015186 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI BUDNEY, ALAN JEFFREY · 2002 to 2017
$7.7M
Training in the Science of Co-Occurring DisordersT32DA037202 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2014 to 2026
$4.7M
Targeting tobacco cessation during treatment for cannabis use disordersR01DA032243 · NIDA · DARTMOUTH COLLEGE · PI BUDNEY, ALAN JEFFREY · 2012 to 2015
$1.7M
NCI NIH HHS P30 CA023108NIDA NIH HHS P30 DA029926NIDA NIH HHS R01 DA015186NIDA NIH HHS R01 DA032243NIDA NIH HHS R01DA032243NIDA NIH HHS T32 DA037202NIDA NIH HHS T32DA037202
6 · The paper itself

Abstract

The proliferation of vaporization ('vaping') as a method for administering cannabis raises many of the same public health issues being debated and investigated in relation to e-cigarettes (e-cigs). Good epidemiological data on the prevalence of vaping cannabis are not yet available, but with current trends towards societal approval of medicinal and recreational use of cannabis, the pros and cons of vaping cannabis warrant study. As with e-cigs, vaping cannabis portends putative health benefits by reducing harm from ingesting toxic smoke. Indeed, vaping is perceived and being sold as a safer way to use cannabis, despite the lack of data on the health effects of chronic vaping. Other perceived benefits include better taste, more efficient and intense effects and greater discretion which allows for use in more places. Unfortunately, these aspects of vaping could prompt an increased likelihood of trying cannabis, earlier age of onset, more positive initial experiences, and more frequent use, thereby increasing the probability of problematic use or addiction. Sales and marketing of vaping devices with no regulatory guidelines, especially related to advertising or product development targeting youth, parallels concerns under debate related to e-cigs and youth. Thus, the quandary of whether or not to promote vaping as a safer method of cannabis administration for those wishing to use cannabis, and how to regulate vaping and vaping devices, necessitates substantial investigation and discussion. Addressing these issues in concert with efforts directed towards e-cigs may save time and energy and result in a more comprehensive and effective public health policy on vaping.

Indexed as

Electronic Nicotine Delivery SystemsMarijuana SmokingSafetyVapingAttitude to HealthHumansMarijuana AbuseMarketingPerceptionPublic HealthRiskCannabise-cigarettesmarijuanapolicyvapingvaporization

Identifiers

PMID26264448
PMCPMC4860523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.